AGA Family of Websites:

Good news: 5 more years of FMT data

Thanks to renewed NIH funding, we will expand our FMT national registry to advance our collective understanding of treatment options for C. difficile infection.
Virus, bacteria or other microbes
Virus, bacteria or other microbes

We are excited to share that NIH has renewed the AGA Fecal Microbiota Transplantation (FMT) National Registry grant — the registry will receive $3.3 million in funding over the next five years. Read on for some of the key goals for the next phase of the registry.

  • Expand the FMT National Registry

    We are continuing to enroll participants who receive FMT for any indication and monitoring short- and long-term safety and effectiveness for up to 10 years after their procedure.

  • Study FMT and LBPs

    We will be diving deeper into the effectiveness of FMT and live biotherapeutic products (LBPs) to treat severe and fulminant C. difficile infection, a high-risk population often excluded in randomized trials.

  • Evaluate shotgun metagenomic sequencing

    We will be expanding our study in partnership with the laboratories of Gail Hecht, MD, MS, AGAF, and Rob Knight, PhD, to characterize the value of shotgun metagenomic sequencing as a platform technology to identify and characterize potentially harmful microbes transmitted by microbiota-based therapies such as FMT or LBPs.